Advances and Challenges in Pediatric Helicobacter pylori-Negative Eosinophilic Gastritis: From Th2-Driven Pathogenesis to Precision Medicine Management
DOI:
https://doi.org/10.61173/71ps3k19Keywords:
Eosinophilic gastritis, EoG, TSLPAbstract
Helicobacter pylori-negative eosinophilic gastritis (EoG) in children remains a diagnostic and therapeutic challenge due to heterogeneous presentation and lack of standardized management. Recent studies have elucidated a Th2-skewed immunopathogenesis driven by key cytokines (IL-5, IL-13) and epithelial-derived chemokines (eotaxin-3, TSLP), which orchestrate eosinophil recruitment and disrupt mucosal integrity. Multimodal diagnostic frameworks that combine quantitative histology (≥30 eos/HPF), high-resolution endoscopic assessment, and molecular biomarkers (e.g., EGDP18 transcript levels, serum TSLP) have enhanced both sensitivity and specificity. Current treatment strategies, including dietary elimination, corticosteroids, and emerging biologics, show variable efficacy and require individualized combination approaches based on severity, tolerability, and safety. However, the field still faces major limitations in standardized outcome metrics, long-term safety data, and guidance for personalized therapy. This review integrates current insights into pediatric EoG immunopathogenesis, diagnostic standardization, treatment paradigms, and translational obstacles, and outlines priorities for future research toward evidence-based, precision medicine strategies. Emerging biomarker panels and multi-omics approaches receive focus for refining patient stratification and monitoring therapeutic responses. Long-term safety assessments and multidisciplinary collaboration are emphasized as essential for advancing novel targeted therapies.
References
of clinical pathways and the improvement of the whole [1] Assa, A., et al. (2022). Helicobacter pylori‐negative Chronic process management level. Gastritis in Children. J Pediatr Gastroenterol Nutr, 75(2), 173– 179. [2] Sindher, S. B., et al. (2023). The Role of Biologics in 6. Conclusions Pediatric Food Allergy and Eosinophilic Gastrointestinal Helicobacter pylori-negative eosinophilic gastritis in Disorders. J Allergy Clin Immunol, 151(3), 595–606. children is a disease in which Th2-dominated immune re- [3] Talley NJ, Shorter RG, Phillips SF, et al. Eosinophilic sponse is the core, and eosinophils cause chronic inflam- gastroenteritis: a clinicopathological study of patients with mation of the gastric mucosa and damage the epithelium disease of the mucosa, muscle layer, and subserosal tissues. Gut through the release of granulin proteins. The current mul- 1990;31:54–8.
timodal integration strategy based on histological diagnos- [4] Virkkula, A., et al. (2022). Prevalence and Clinical tic criteria (≥30 eos/HPF) combined with endoscopic mor- Significance of Helicobacter pylori‐negative Gastritis in phology, molecular markers (e.g., eotaxin-3, TSLP, IL-5) Children. J Pediatr Gastroenterol Nutr, 75(2), 180–186.
and EGDP18 expression models is expected to signifi- [5] Shoda, T., et al. (2020). Eosinophilic gastritis is characterized cantly improve the diagnostic sensitivity and specificity of by an eosinophil-predominant inflammatory gene signature and EoG, early identification and accurate stratification. At the molecular overlap with eosinophilic esophagitis. J Allergy Clin therapeutic level, dietary interventions, glucocorticoids Immunol, 145(3), 945–958.
and targeted biologics have their own adaptations and [6] Kagalwalla, A. F., et al. (2006). Effect of six-food elimination limitations at different stages of the disease, and it is nec- diet on clinical and histologic outcomes in eosinophilic essary to formulate a dynamically adjusted individualized esophagitis. Clin Gastroenterol Hepatol, 4(9), 1097–1102.
combination plan based on the severity of the disease, the [7] Henderson, C. J., et al. (2012). Comparative dietary therapy compliance of children and the risk of adverse reactions. effectiveness in remission of pediatric eosinophilic esophagitis. J In the face of bottlenecks such as inconsistent efficacy Allergy Clin Immunol, 129(6), 1570–1578.
evaluation criteria, insufficient follow-up data and lack of [8] Lucendo, A. J., et al. (2015). Systematic review: the efficacy evidence-based support for individualized treatment, it is and safety of topical corticosteroids in eosinophilic esophagitis. urgent to build a unified efficacy evaluation system cover- Aliment Pharmacol Ther, 41(9), 844–859.
ing clinical symptoms, histology and molecular indicators, [9] Dohil, R., et al. (2010). Oral viscous budesonide is establish a multi-center long-term follow-up database to effective in children with eosinophilic gastroenteritis. J Pediatr systematically monitor the recurrence rate and drug safety, Gastroenterol Nutr, 50(5), 529–534.
and carry out prospective verification of Th2 cell subsets [10] Dellon, E. S., et al. (2021). Anti–IL-13 monoclonal antibody and related biomarkers. At the same time, the standardized for eosinophilic esophagitis. N Engl J Med, 385(4), 330–341.
process and resource allocation of multidisciplinary col- [11] Gleich, G. J., et al. (2013). The consequences of not having laboration platforms such as gastroenterology, pathology, eosinophils. Allergy, 68(7), 829–835.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
